Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 7/2010

01-07-2010 | Original Paper

Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer

Authors: José M. del Casar, Guillermo Carreño, Luis O. González, Sara Junquera, Salomé González-Reyes, José M. González, Miguel Bongera, Antonio M. Merino, Francisco J. Vizoso

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2010

Login to get access

Abstract

Aims

To investigate the expression of matrix metalloproteases (MMPs) and their inhibitors (TIMPs) in patients who develop local recurrence (LR) after mastectomy.

Methods

We analyzed the expressions of MMP-1, -2, -7, -9, -11, -13, -14, TIMP-1, -2, and -3, using immunohistochemical techniques, in primary tumors from patients without tumoral recurrence (n = 50), patients who developed distant metastasis (n = 50), and from patients who develop LRs (n = 25). LRs of the latter group were also analyzed for MMPs expression. All the patients underwent mastectomy.

Results

Score values for all MMPs and TIMPs were significantly higher in primary tumors of patients with distant metastasis. Primary tumors from patients with LR have lower expressions of MMPs and TIMPs compared with those from patients who developed distant metastasis, and with patients without recurrence for some MMPs. Remarkably, however, primary tumors from patients with LR showed significantly higher percentage of TIMP-1 and 2 expression in stromal cells compared to primary tumors from patients with distant metastasis or primary tumors from patients without tumoral progression. Furthermore, LRs had significantly higher MMP-9 expression than their corresponding primary tumors.

Conclusions

Our data indicate differences in MMPs/TIMPs expression between primary tumors of patients with LRs and of those with distant metastasis, both after mastectomy for breast cancer.
Literature
Aberizk WJ, Silver B, Henderson IC, Cady B, Harris JR (1986) The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 58:1214–1218CrossRefPubMed
Alexander JW, Altemeier WA (1964) Susceptibility of injured tissues to hematogenous metastases: an experimental study. Ann Surg 159:933–944CrossRefPubMed
Auchincloss H Jr (1958) The nature of local recurrence following radical mastectomy. Cancer 11:611–619CrossRefPubMed
Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC (1999) Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79:1347–1355CrossRefPubMed
Baker EA, Stephenson TJ, Reed MW, Brown NJ (2002) Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol 55:300–304CrossRefPubMed
Baral E, Ogenstad S, Wallgren A (1985) The effect of adjuvant radiotherapy on the time of occurrence and prognosis of local recurrence in primary operable breast cancer. Cancer 56:2779–2782CrossRefPubMed
Barnes R, Masood S, Barker E et al (1991) Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol 139:245–250PubMed
Bedwinek J (1994) Natural history and management of isolated local-regional recurrence following mastectomy. Semin Radiat Oncol 4:260–269CrossRefPubMed
Bedwinek JM, Lee J, Fineberg B, Ocwieza M (1981) Prognostic indicators in patients with isolated local-regional recurrence of breast cancer. Cancer 47:2232–2235CrossRefPubMed
Berstock DA, Houghton J, Haybittle J, Baum M (1985) The role of radiotherapy following total mastectomy for patients with early breast cancer. World J Surg 9:667–670CrossRefPubMed
Borner M, Bacchi M, Goldhirsch A et al (1994) First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 12:2071–2077PubMed
Carreno G, Del Casar JM, Corte MD et al (2007) Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics. Breast Cancer Res Treat 102:61–73CrossRefPubMed
Chantrain CF, Shimada H, Jodele S et al (2004) Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 64:1675–1686CrossRefPubMed
Cornelius LA, Nehring LC, Harding E et al (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161:6845–6852PubMed
Crile G Jr (1972) Low incidence and morbidity of local recurrence after conservative operations for cancer of the breast. Ann Surg 175:249–253CrossRefPubMed
Dao TL, Nemoto T (1963) The clinical significance of skin recurrence after radical mastectomy in women with cancer of the breast. Surg Gynecol Obstet 117:447–453PubMed
Dao TL, Yogo H (1967) Enhancement of pulmonary metastases by x-irradiation in rats bearing mammary cancer. Cancer 20:2020–2025CrossRefPubMed
Dixon AR, Ellis IO, Elston CW, Blamey RW (1991) A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer 63:634–635PubMed
Donegan WL, Perez-Mesa CM, Watson FR (1966) A biostatistical study of locally recurrent breast carcinoma. Surg Gynecol Obstet 122:529–540PubMed
Dong Z, Kumar R, Yang X, Fidler IJ (1997) Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88:801–810CrossRefPubMed
Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2:252–257CrossRefPubMed
Durkan GC, Nutt JE, Marsh C et al (2003) Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer. Clin Cancer Res 9:2576–2582PubMed
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174CrossRefPubMed
Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J (2000) Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486:247–251CrossRefPubMed
Fidler IJ, Zeidman I (1972) Enhancement of experimental metastasis by X-ray: a possible mechanism. J Med 3:172–177PubMed
Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM (2001) Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3:459–468CrossRefPubMed
Fisher B, Fisher ER (1959) Experimental studies of factors influencing hepatic metastases. III. Effect of surgical trauma with special reference to liver injury. Ann Surg 150:731–744CrossRefPubMed
Fisher B, Redmond C, Fisher ER (1980) The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology—an overview of findings. Cancer 46:1009–1025CrossRefPubMed
Gilliland MD, Barton RM, Copeland EM 3rd (1983) The implications of local recurrence of breast cancer as the first site of therapeutic failure. Ann Surg 197:284–287CrossRefPubMed
Gonzalez LO, Pidal I, Junquera S et al (2007) Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer 97:957–963CrossRefPubMed
Grieu F, Li WQ, Iacopetta B (2004) Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 88:197–204CrossRefPubMed
Jiang Y, Goldberg ID, Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21:2245–2252CrossRefPubMed
Jones JL, Walker RA (1997) Control of matrix metalloproteinase activity in cancer. J Pathol 183:377–379CrossRefPubMed
Jones JL, Glynn P, Walker RA (1999) Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 189:161–168CrossRefPubMed
Kaae S, Johansen H (1962) Breast cancer; five year results: two random series of simple mastectomy with postoperative irradiation versus extended radical mastectomy. Am J Roentgenol Radium Ther Nucl Med 87:82–88PubMed
Kamby C, Sengelov L (1999) Survival and pattern of failure following locoregional recurrence of breast cancer. Clin Oncol (R Coll Radiol) 11:156–163
Kamby C, Andersen J, Ejlertsen B et al (1991) Pattern of spread and progression in relation to the characteristics of the primary tumour in human breast cancer. Acta Oncol 30:301–308CrossRefPubMed
Karabali-Dalamaga S, Souhami RL, O’Higgins NJ, Soumilas A, Clark CG (1978) Natural history and prognosis of recurrent breast cancer. Br Med J 2:730–733CrossRefPubMed
Lacour J, Le M, Caceres E, Koszarowski T, Veronesi U, Hill C (1983) Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer 51:1941–1943CrossRefPubMed
Lacour J, Le MG, Hill C, Kramar A, Contesso G, Sarrazin D (1987) Is it useful to remove internal mammary nodes in operable breast cancer? Eur J Surg Oncol 13:309–314PubMed
Li HC, Cao DC, Liu Y et al (2004) Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 88:75–85CrossRefPubMed
Liotta LA, Kohn EC (2001) The microenvironment of the tumour–host interface. Nature 411:375–379CrossRefPubMed
Manes S, Llorente M, Lacalle RA et al (1999) The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274:6935–6945CrossRefPubMed
McCarthy K, Maguire T, McGreal G, McDermott E, O’Higgins N, Duffy MJ (1999) High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 84:44–48CrossRefPubMed
Mimori K, Ueo H, Shirasaka C, Mori M (2001) Clinical significance of MT1-MMP mRNA expression in breast cancer. Oncol Rep 8:401–403PubMed
Nakopoulou L, Giannopoulou I, Stefanaki K et al (2002) Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 197:307–313CrossRefPubMed
Nielsen BS, Rank F, Lopez JM et al (2001) Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res 61:7091–7100PubMed
Noe V, Fingleton B, Jacobs K et al (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111–118PubMed
Orel SG, Schnall MD, Powell CM et al (1995) Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology 196:115–122PubMed
Papaioannou AN (1985) Hypothesis: increasingly intensive locoregional treatment of breast cancer may promote recurrence. J Surg Oncol 30:33–41CrossRefPubMed
Parker RL, Huntsman DG, Lesack DW et al (2002) Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 117:723–728CrossRefPubMed
Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10:7621–7628CrossRefPubMed
Pineiro A, Salinas J, Illana J et al (2004) Locoregional recurrence and metastasis in the long-term follow-up of postmastectomy breast cancer patients with T1–T2 tumors and one to three positive lymph nodes. Rev Oncol 6:341–346
Pisansky TM, Ingle JN, Schaid DJ et al (1993) Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer 72:1247–1260CrossRefPubMed
Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997) High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 3:1623–1628PubMed
Remacle A, McCarthy K, Noel A et al (2000) High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 89:118–121CrossRefPubMed
Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J (1999) Proteolytic control of growth factor availability. Apmis 107:80–85CrossRefPubMed
Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M (2001) Tissue microarray: a new technology for amplification of tissue resources. Cancer J 7:24–31PubMed
Scanlon EF (1985) Local recurrence in the pectoralis muscles following modified radical mastectomy for carcinoma. J Surg Oncol 30:149–151PubMedCrossRef
Schrohl AS, Christensen IJ, Pedersen AN et al (2003) Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2:164–172CrossRefPubMed
Schrohl AS, Holten-Andersen MN, Peters HA et al (2004) Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 10:2289–2298CrossRefPubMed
Schuck A, Konemann S, Matthees B et al (2002) Radiotherapy in the treatment of locoregional relapses of breast cancer. Br J Radiol 75:663–669PubMed
Sivula A, Talvensaari-Mattila A, Lundin J et al (2005) Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 89:215–220CrossRefPubMed
Skipper D, Jeffrey MJ, Cooper AJ, Alexander P, Taylor I (1989) Enhanced growth of tumour cells in healing colonic anastomoses and laparotomy wounds. Int J Colorectal Dis 4:172–177CrossRefPubMed
Stefanik D, Goldberg R, Byrne P et al (1985) Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 3:660–665PubMed
Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516CrossRefPubMed
Stetler-Stevenson WG (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103:1237–1241CrossRefPubMed
Sykes HF, Sim DA, Wong CJ, Cassady JR, Salmon SE (1989) Local-regional recurrence in breast cancer after mastectomy and adriamycin-based adjuvant chemotherapy: evaluation of the role of postoperative radiotherapy. Int J Radiat Oncol Biol Phys 16:641–647PubMed
Symmans WF, Ayers M, Clark EA et al (2003) Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97:2960–2971CrossRefPubMed
Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T (2001) Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 65:55–61CrossRefPubMed
Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89:1270–1275CrossRefPubMed
Toonkel LM, Fix I, Jacobson LH, Wallach CB (1983) The significance of local recurrence of carcinoma of the breast. Int J Radiat Oncol Biol Phys 9:33–39PubMed
Turk V, Kos J, Turk B (2004) Cysteine cathepsins (proteases)—on the main stage of cancer? Cancer Cell 5:409–410CrossRefPubMed
Valagussa P, Bonadonna G, Veronesi U (1978) Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 41:1170–1178CrossRefPubMed
van Tienhoven G, Voogd AC, Peterse JL et al (1999) Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer 35:32–38CrossRefPubMed
Veronesi U, Marubini E, Del Vecchio M et al (1995) Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 87:19–27CrossRefPubMed
Visscher DW, Hoyhtya M, Ottosen SK et al (1994) Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59:339–344CrossRefPubMed
Vizoso FJ, Gonzalez LO, Corte MD et al (2007a) Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 96:903–911CrossRefPubMed
Vizoso FJ, Rodriguez M, Altadill A et al (2007b) Liver expression of steroid hormones and apolipoprotein D receptors in hepatocellular carcinoma. World J Gastroenterol 13:3221–3227PubMed
Willner J, Kiricuta IC, Kolbl O (1997) Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 37:853–863PubMed
Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163–176PubMed
Metadata
Title
Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer
Authors
José M. del Casar
Guillermo Carreño
Luis O. González
Sara Junquera
Salomé González-Reyes
José M. González
Miguel Bongera
Antonio M. Merino
Francisco J. Vizoso
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 7/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-009-0750-x

Other articles of this Issue 7/2010

Journal of Cancer Research and Clinical Oncology 7/2010 Go to the issue

Original Paper

Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy

Original Paper

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors

Original Paper

Interaction between glutathione-S-transferase polymorphisms, smoking habit, and HPV infection in cervical cancer risk

Original Paper

The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study

Original Paper

FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis

Original Paper

Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits